Company research
InMed Pharmaceuticals Inc.
CIK 1728328Updated Nov 13, 2026
SecurityMTRI · NASDAQ · equity
Historical securities (2)
IMLFF · OTC · equity · closed Nov 10, 2020IMLWF · OTC · warrant · closed Jun 23, 2020MTRI price & chart
Loading TradingView…
NASDAQ:MTRI on TradingView ↗About the company
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. For more information, visit www.inmedpharma.com.
In the news
Recent filings
Show 5 more recent filings
3 filing
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Results of Operations and Financial Condition · Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Changes in Control of Registrant · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics · Change in Shell Company Status
Items 1.01, 2.01, 2.02, 3.02, 3.03, 5.01, 5.02, 5.03, 5.05, 5.06, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders · Other Events
Items 5.03, 5.07, 8.01, 9.01
Financials
FY 2026 · USDSource
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 9,133,806Source | 9,279,834Source | — | 11,191,484Source | 8,502,292Source | 15,255,464Source | 13,361,085Source | 10,465,106Source | 3,030,067Source | 15,580,040Source | 11,822,782Source | 14,106,340Source |
| Property, Plant and Equipment, NetUSD | 642,884Source | 1,108,662Source | — | 764,254Source | 1,230,961Source | 1,481,102Source | 881,549Source | 1,343,009Source | 221,037Source | 992,199Source | 1,249,999Source | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 1,498,473Source | 1,661,109Source | — | 1,538,576Source | 1,701,211Source | 1,864,292Source | 1,579,569Source | 1,742,205Source | — | 1,620,562Source | 1,783,198Source | 1,946,279Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,158,932Source | 4,679,826Source | — | 6,954,834Source | 3,419,422Source | 9,534,922Source | 9,331,077Source | 5,583,039Source | — | 11,075,871Source | 6,571,610Source | 8,912,517Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 367,813Source | — | 182,967Source | 262,569Source | 372,870Source | 343,469Source | 284,695Source | — | 465,104Source | 352,838Source | 260,399Source |
| Inventory, NetUSD | — | 813,970Source | — | 947,898Source | 1,103,356Source | 744,839Source | 890,807Source | 1,220,073Source | — | 961,173Source | 1,244,324Source | 1,616,356Source |
| Assets, CurrentUSD | 6,888,081Source | 6,410,063Source | — | 8,788,654Source | 5,470,120Source | 11,810,070Source | 10,799,967Source | 7,279,892Source | 2,676,706Source | 12,867,279Source | 8,689,585Source | 11,331,727Source |
| Prepaid Expense and Other Assets, CurrentUSD | 617,211Source | 507,872Source | — | 660,280Source | 643,986Source | 1,112,977Source | 191,755Source | 148,882Source | 241,296Source | 321,747Source | 477,749Source | 498,033Source |
| Other Assets, NoncurrentUSD | 104,368Source | 100,000Source | — | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 132,324Source | 100,000Source | 100,000Source | 104,908Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 2,242,032Source | 2,258,309Source | — | 1,603,820Source | 2,320,192Source | 2,483,253Source | 1,770,462Source | 2,069,662Source | 1,955,060Source | 2,145,545Source | 2,616,673Source | 2,016,613Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 92,578,071Source | 87,457,095Source | — | 92,046,396Source | 84,537,194Source | 79,936,633Source | 91,806,396Source | 84,198,673Source | 94,282,698Source | 91,221,174Source | 82,784,400Source | 77,620,252Source |
| Additional Paid in CapitalUSD | — | — | — | — | — | 38,122,231Source | — | — | — | — | — | 35,741,115Source |
| Retained Earnings (Accumulated Deficit)USD | -123,959,350Source | -115,449,581Source | — | -120,993,014Source | -113,328,651Source | -105,415,222Source | -118,964,791Source | -110,753,627Source | -130,230,406Source | -117,237,892Source | -109,075,759Source | -101,400,209Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 128,569Source | 128,569Source | — | 128,569Source | 128,569Source | 128,569Source | 128,569Source | 128,569Source | 128,569Source | 128,569Source | 128,569Source | 128,569Source |
| Stockholders' Equity Attributable to ParentUSD | 6,891,774Source | 7,021,525Source | 11,104,650Source | 9,587,664Source | 6,182,100Source | 12,772,211Source | 11,590,623Source | 8,395,444Source | 1,075,007Source | 13,434,495Source | 9,206,109Source | 12,089,727Source |
| Additional Paid in Capital, Common StockUSD | 38,144,484Source | 34,885,442Source | — | 38,405,713Source | 34,844,988Source | — | 38,620,449Source | 34,821,829Source | 36,894,146Source | 39,322,644Source | 35,368,899Source | — |
| Liabilities and EquityUSD | 9,133,806Source | 9,279,834Source | — | 11,191,484Source | 8,502,292Source | 15,255,464Source | 13,361,085Source | 10,465,106Source | 3,030,067Source | 15,580,040Source | 11,822,782Source | 14,106,340Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,211,266Source | 1,838,962Source | — | 1,479,993Source | 1,790,944Source | 1,680,469Source | 1,554,984Source | 1,435,879Source | 1,955,060Source | 1,839,790Source | 1,971,808Source | 2,000,619Source |
| Operating Lease, Liability, CurrentUSD | 389,381Source | 429,247Source | — | 408,122Source | 419,711Source | 364,190Source | 424,765Source | 424,260Source | — | 435,507Source | 317,797Source | 375,713Source |
| Accounts Payable, CurrentUSD | — | — | — | — | — | — | — | 2,000Source | — | — | 41,004Source | — |
| Operating Lease, Liability, NoncurrentUSD | 30,766Source | 419,347Source | — | 123,827Source | 529,248Source | 802,784Source | 215,478Source | 633,783Source | — | 305,755Source | 644,865Source | 15,994Source |
| Additional Financial Items | ||||||||||||
| Accounts Receivable, after Allowance for Credit LossUSD | — | — | — | — | — | 66,775Source | — | — | — | 1,952,363Source | — | 66,775Source |
| Accrued Liabilities, CurrentUSD | — | — | — | — | — | 100,446Source | — | 85,521Source | — | — | 256,473Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 5,200,000Source | 4,700,000Source | — | 7,000,000Source | 3,500,000Source | 9,500,000Source | 9,400,000Source | 5,600,000Source | 2,200,000Source | 11,100,000Source | 6,600,000Source | — |
| Short-term InvestmentsUSD | 41,625Source | 40,582Source | — | 42,675Source | 40,787Source | 44,462Source | 42,859Source | 43,203Source | 39,670Source | 43,384Source | 43,064Source | 44,422Source |
cash flow · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 7,900,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 53,202Source | 54,579Source | 205,271Source | 212,839Source | 219,600Source | 202,249Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 20,205Source | 28,964Source | 106,866Source | 119,307Source | 137,714Source | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -122,160Source | -67,624Source | — | 114,690Source | 92,439Source | 219,147Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -70,366Source | -24,251Source | — | -283,151Source | -66,220Source | -565,561Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,607,616Source | -1,826,810Source | -8,643,513Source | -7,766,951Source | -6,985,832Source | -7,283,199Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | -9,293Source | -661,804Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 1,790Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | 9,293Source | 160,014Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -137,178Source | 838,239Source | 94,496Source | 12,271,212Source | 4,654,218Source | 10,680,654Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | — | -2,340,907Source | 2,735,651Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 5,158,932Source | 4,679,826Source | 6,954,834Source | 3,419,422Source | 9,331,077Source | 5,583,039Source | 2,194,413Source | 11,075,871Source | 6,571,610Source | 8,912,517Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 38,771Source | 40,454Source | 25,564Source | 23,159Source | 20,205Source | 28,964Source | 106,866Source | 119,307Source | 137,714Source | 278,154Source |
| Amortization of Intangible AssetsUSD | — | — | 41,000Source | 41,000Source | 41,000Source | 41,000Source | 41,000Source | 41,000Source | 162,636Source | 162,636Source | 171,858Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 5,200,000Source | 4,700,000Source | 7,000,000Source | 3,500,000Source | 9,400,000Source | 5,600,000Source | 2,200,000Source | 11,100,000Source | 6,600,000Source | — |
| DepreciationUSD | — | — | — | 12,203Source | — | 12,209Source | — | 13,586Source | — | 50,204Source | 47,742Source | — |
| Equipment ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 700,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -23,168Source | -22,165Source | 18,136Source | -47,753Source | -56,994Source | 19,310Source | -58,009Source | -28,471Source | — | — |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | -1,358Source | -5,270Source | -7,151Source | — | -61,921Source | -48,175Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | -7,136Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | -7,136Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 1,742,016Source | 1,584,393Source | 1,621,095Source | 1,718,774Source | 1,532,015Source | 1,492,961Source | 6,661,372Source | 6,557,822Source | 5,250,715Source | 5,847,518Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 1,457,926Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | -2,791,751Source | -2,067,069Source | — | — | — | — | -11,373,141Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -174,585Source | -53,861Source | — | — | — | — | -1,187,709Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | 7,100Source | 13,100Source |
| Inventory Write-downUSD | — | — | — | 0Source | 208,737Source | — | 208,737Source | 0Source | — | — | 305,812Source | 308,937Source |
| Investment Income, InterestUSD | — | — | 47,770Source | 16,565Source | 74,379Source | 30,536Source | 93,765Source | 57,094Source | 244,971Source | 155,882Source | 527,901Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,966,336Source | -2,120,930Source | -2,028,223Source | -2,575,024Source | -1,726,899Source | -1,677,868Source | -12,560,850Source | -8,162,133Source | -7,675,550Source | -7,947,622Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | -12,992,514Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | 527,901Source | — |
| Operating ExpensesUSD | — | — | 2,839,521Source | 2,083,634Source | 2,286,796Source | 2,714,905Source | 2,223,823Source | 2,228,375Source | 11,607,412Source | 9,653,052Source | 9,297,264Source | 9,781,823Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | — | 431,165Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | — | — | — | 1,319,782Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 12,000,436Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | — | 1,365,755Source |
income statement · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 1,261,578Source | 820,188Source | 1,111,707Source | 1,120,121Source | 1,264,638Source | — | 4,942,633Source | 4,597,730Source | 4,135,561Source |
| Cost of Goods and Services Sold | — | — | — | —Source | —Source | —Source | —Source | —Source | — | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | — | — | — | — | — | — | — | — | — | -7,947,622Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | — | 431,165Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -2,791,751Source | -2,067,069Source | -2,028,223Source | -2,575,024Source | -1,726,899Source | -1,677,868Source | -11,373,141Source | -8,162,133Source | -7,668,450Source | -7,934,522Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | 7,100Source | 13,100Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,966,336Source | -2,120,930Source | -2,028,223Source | -2,575,024Source | -1,726,899Source | -1,677,868Source | -12,560,850Source | -8,162,133Source | -7,675,550Source | -7,947,622Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.73Source | -1.94Source | -0.51Source | -3.64Source | -0.44Source | -2.71Source | -3.12Source | -8.36Source | -1.01Source | -3.25Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.73Source | -1.94Source | -0.51Source | -3.64Source | -0.44Source | -2.71Source | -3.12Source | -8.36Source | -1.01Source | -3.25Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 4,048,209Source | 1,095,973Source | 3,954,549Source | 706,546Source | 3,954,549Source | 620,127Source | 4,163,598Source | 975,985Source | 7,621,075Source | 2,448,458Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 4,048,209Source | 1,095,973Source | 3,954,549Source | 706,546Source | 3,954,549Source | 620,127Source | 4,163,598Source | 975,985Source | 7,621,075Source | 2,448,458Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 41,000Source | 41,000Source | 41,000Source | 41,000Source | 41,000Source | 41,000Source | 162,636Source | 162,636Source | 171,858Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 51,707Source | 51,706Source | 53,201Source | 53,202Source | 53,202Source | 54,579Source | 205,271Source | 212,839Source | 219,600Source | 202,249Source |
| Equipment ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 700,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -23,168Source | -22,165Source | 18,136Source | -47,753Source | -56,994Source | 19,310Source | -58,009Source | -28,471Source | — | — |
| General and Administrative ExpenseUSD | — | — | 1,742,016Source | 1,584,393Source | 1,621,095Source | 1,718,774Source | 1,532,015Source | 1,492,961Source | 6,661,372Source | 6,557,822Source | 5,250,715Source | 5,847,518Source |
| Gross ProfitUSD | — | — | — | 175,625Source | 184,194Source | 460,894Source | 403,159Source | 493,413Source | — | 1,706,586Source | 1,100,913Source | 1,403,036Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | -2,791,751Source | -2,067,069Source | — | — | — | — | -11,373,141Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | -0.69Source | -1.89Source | — | — | — | — | -2.84Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | -0.69Source | -1.89Source | — | — | — | — | -2.84Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -174,585Source | -53,861Source | — | — | — | — | -1,187,709Source | — | — | — |
| Interest Income, OtherUSD | — | — | — | — | — | — | — | — | — | — | — | 492,440Source |
| Investment Income, InterestUSD | — | — | 47,770Source | 16,565Source | 74,379Source | 30,536Source | 93,765Source | 57,094Source | 244,971Source | 155,882Source | 527,901Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | -12,992,514Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | 527,901Source | — |
| Operating ExpensesUSD | — | — | 2,839,521Source | 2,083,634Source | 2,286,796Source | 2,714,905Source | 2,223,823Source | 2,228,375Source | 11,607,412Source | 9,653,052Source | 9,297,264Source | 9,781,823Source |
| Other General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 369,239Source |
| Research and Development ExpenseUSD | — | — | 1,022,630Source | 425,370Source | 630,636Source | 895,176Source | 581,612Source | 700,145Source | 3,028,473Source | 2,853,920Source | 3,765,028Source | 3,732,056Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | — | — | — | — | 1,365,755Source |
Offerings
Registration 333-297234
Filing attachments
d539218dex107.htm · 8-K · 2026-11-10
Exhibit 10.7 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. CONTINGENT VALUE RIGHTS AGREEMENT This CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of November 6, 2026, is entered into by and between Mentari Therapeutics, Inc. (formerly known as InMed Pharma…
Read attachment ↗d539218dex991.htm · 8-K · 2026-11-10
Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below shall have the same meaning as terms defined and included in the Company’s definitive proxy statement/prospectus filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 1, 2026 (the “Proxy Statement/Prospectus”). On May 19, 2026, Mentari entered into a Merger Agreement, which was subsequently amended on July 6, 2026, with InMed and Indigo Merger Sub Corp and Indigo Merg…
Read attachment ↗d183007dex991.htm · 8-K · 2026-11-09
Exhibit 99.1 Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million Financing Mentari is advancing a robust pipeline of biologics for the prevention of migraine, including MT-001 and MT-002, which target clinically validated pathways and have potential to address the two-thirds of people who have a suboptimal response to existing anti-CGRP therapies Phase 1 clinical trial for MT-001, a monoclonal antibody targeting PACAP, ongoing with…
Read attachment ↗d173223dex991.htm · 8-K · 2026-11-05
Exhibit 99.1 NASDAQ: INM 1800 – 510 West Georgia St. Vancouver, BC, Canada V6B 0M3 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation Vancouver, British Columbia - November 4, 2026. InMed Pharmaceuticals Inc. (now Mentari Therapeutics, Inc.) (NASDAQ: INM) (the “Company”), a pharmaceutical company focused on develo…
Read attachment ↗ea030576901ex99-1.htm · 8-K · 2026-09-18
EX-99.1 2 ea030576901ex99-1.htm PRESS RELEASE Exhibit 99.1 Nasdaq: INM c/o Norton Rose Fulbright Canada LLP Suite 1800-510 West Georgia St. Vancouver, BC, Canada V6B 0M3 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Stockholders’ Equity Compliance Vancouver, BC - September 18, 2026 - InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pharmaceutical comp…
Read attachment ↗ea029864401ex99-1.htm · 425 · 2026-07-22
Exhibit 99.1 Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline WALTHAM, Mass., July 22, 2026 - Mentari Therapeutics, Inc. (“Mentari”), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $200 million private placement to leading healthcare investors. The proceeds from the private placement will enable the continued development of Mentari’s pipeline of targeted biologics aimed at improving outcomes f…
Read attachment ↗